# Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC

> **NCT06711094** · NA · NOT_YET_RECRUITING · sponsor: **Fujian Medical University** · enrollment: 52 (estimated)

## Conditions studied

- HR+/HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib

## Key facts

- **NCT ID:** NCT06711094
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711094, "Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06711094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*